ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Imaging"

  • Abstract Number: 1710 • ACR Convergence 2025

    Defining sonographic enthesitis in psoriatic arthritis: Developing a data- and expert-driven definition for inflammatory enthesitis at the single enthesis level

    Andre Lucas Ribeiro1, Sibel Aydin2, Gurjit Kaeley3, Fahmeen J. Afgani4, Catherine Bakewell5, Marcos Rosemffet6, Minna Kohler7, Amir Haddad8, Maria S. Stoenoiu9, Ari Polachek10, josefina marin11, Arnon Katz12, Sahil Koppikar13 and Lihi Eder14, 1Hospital de Clínicas de Porto Alegre, Porto Alegre, Rio Grande do Sul, Brazil, 2Department of Medicine, University of Ottawa, The Ottawa Hospital Research Institute, Ottawa, ON, Canada, 3UF COM-J, Ponte Vedra Beach, FL, 4Women's College Hospital, Toronto, Canada, 5Intermountain Healthcare, Salt Lake City, UT, 6Instituto de Rehabilitación Psicofísica, Capital Federal, Argentina, 7Massachusetts General Hospital, Harvard Medical School, Boston, MA, 8Carmel Medical Centre, Haifa, Israel, 9Cliniques Universitaires Saint-Luc, Brussels, Belgium, 10Rheumatology Institute of Beilinson Hospital, Petah Tikva, Israel, 11Hospital Universitario Rey Juan Carlos, Madrid, Spain, 12GRAPPA, Seattle, 13Women's College Hospital & University of Toronto, Markham, ON, Canada, 14University of Toronto, Toronto, ON, Canada

    Background/Purpose: Enthesitis affects 30–40% of PsA patients but remains difficult to diagnose due to overlap with non-specific entheseal pain. While OMERACT has standardized ultrasound (US)…
  • Abstract Number: 1239 • ACR Convergence 2025

    JAK inhibition appears to alter clinical and neurobiological markers of nociplastic pain in rheumatoid arthritis: a 7T MRI Brain study

    Kristian Stefanov1, Andrew McGucken1, Maxine Arnott1, Tyrone Lau1, Norah Aldehmi1, Vinod Kumar2, Neil McKay3, James Dale4, Lindsay Robertson5, James Brock1, Flavia Sunzini6 and Neil Basu7, 1University of Glasgow, Glasgow, United Kingdom, 2NHS Tayside, Dundee, United Kingdom, 3NHS Lothian, Edinburgh, United Kingdom, 4NHS Lanarkshire, Wishaw, United Kingdom, 5NHS Grampian, Aberdeen, United Kingdom, 6Glasgow University, Glasgow, United Kingdom, 7Institute of Infection, Immunity & Inflammation, University of Glasgow, Glasgow, United Kingdom

    Background/Purpose: Pain remains a prevalent and highly impactful issue for people with rheumatoid arthritis (RA). Among modern day targeted therapies, the janus kinase (JAK) inhibitors…
  • Abstract Number: 0878 • ACR Convergence 2025

    Effects of IL-17A Inhibition on Entheseal Osteoblast and Fibroblast Dynamics in Psoriatic Arthritis: Insights from the EBIO Biopsy Study

    Maria Gabriella Raimondo1, Hashem Mohammadian2, Simon Rauber3, Stefano Alivernini4, Filippo Fagni5, Giulia Corte6, Koray Tascilar7, Alina Mihaela Ramming8, Juergen Rech2, Maria Antonietta D´Agostino9, Georg Schett2, Milena Pachowsky8, Arnd Kleyer10 and Andreas Ramming11, 1Department of Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, 2Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany, Erlangen, Germany, 3Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany, Erlangen, Bayern, Germany, 4Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, 5Department of Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-Universität Erlangen-Nürnberg and University Hospital Erlangen, Erlangen, Bayern, Germany, 6- Department of Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-Universität Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, Erlangen, Germany, 7Department of Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-Universität Erlangen-Nürnberg and University Hospital Erlangen, Erlangen, Germany, 8Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, 94Division of Rheumatology - Fondazione Policlinico Universitario A. Gemelli IRCCS - Università Cattolica del Sacro Cuore, Rome, Italy, 10Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany, Berlin, Germany, 11Department of Internal Medicine 3, Rheumatology & Immunology, Friedrich-Alexander-University (FAU) & Universitätsklinikum Erlangen, Erlangen, Germany

    Background/Purpose: Enthesitis is an early event in the course of psoriatic arthritis (PsA) and a hallmark feature of the disease. Currently, much of the understanding…
  • Abstract Number: 0242 • ACR Convergence 2025

    Contemporary Recurrent Pericarditis Management – Real-world Evidence of Limited Cardiac Magnetic Resonance Imaging Prior to Initiating Rilonacept

    Brittany Weber1, Paul Cremer2, Michael Garshick3, Sushil Allen Luis4, Ajit Raisinghani5, Vidhya Parameswaran6, Allison Curtis6, Allan Klein7 and John Paolini6, 1Brigham and Women's Hospital, DEDHAM, MA, 2Cleveland Clinic, Shaker Heights, OH, 3NYU Langone Health, Tenafly, NJ, 4Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, 5Division of Cardiology, Department of Medicine, Sulpizio Cardiovascular Center, University of California San Diego, San Diego, CA, 6Kiniksa Pharmaceuticals, LEXINGTON, MA, 7Cleveland Clinic, Cleveland, OH

    Background/Purpose: Recurrent pericarditis (RP) is a chronic autoinflammatory disease (mediated by IL-1) that requires long-term treatment, and selection of therapy is guided by multiple factors.…
  • Abstract Number: 2613 • ACR Convergence 2025

    Ga-FAPI-04 PET/CT reveals increased fibroblast activation in synovial and enthesial tissues of psoriasis patients with arthralgia and predicts the development of psoriatic arthritis

    Giulia Corte1, Koray Tascilar2, armin Atzinger3, Alp Temiz2, Melek Yalcin Mutlu4, Rita Noversa de Sousa5, Maria Gabriella Raimondo6, Andreas Ramming7, Sara Bayat2, Michael Sticherling8, Torsten Kuwert9, Christian Schmidkonz9, Georg Schett10 and Filippo Fagni11, 1- Department of Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-Universität Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, Erlangen, Germany, 2Department of Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-Universität Erlangen-Nürnberg and University Hospital Erlangen, Erlangen, Germany, 3Department of Nuclear Medicine, Friedrich-Alexander University (FAU) Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany, Erlangen, Germany, 4Department of Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-Universität Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, erlangen, 5Department of Internal Medicine 3, Friedrich-Alexander University (FAU) Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany, Erlangen, 6Department of Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, 7Department of Internal Medicine 3, Rheumatology & Immunology, Friedrich-Alexander-University (FAU) & Universitätsklinikum Erlangen, Erlangen, Germany, 8Department of Dermatology, Friedrich-Alexander University (FAU) Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany, Erlangen, Germany, 9Department of Nuclear Medicine, Friedrich-Alexander University (FAU) Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany, Erlangen, 10Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany, Erlangen, Germany, 11Department of Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-Universität Erlangen-Nürnberg and University Hospital Erlangen, Erlangen, Bayern, Germany

    Background/Purpose: 68Ga-FAPI-04 PET/CT reveals fibroblast activation in vivo and is increasingly used to assess rheumatic diseases, including inflammatory arthritides. (1,2) We previously demonstrated that the…
  • Abstract Number: 2081 • ACR Convergence 2025

    Radiologic surveillance in the Phase II RCT of LEVI-04, a novel neurotrophin-3 inhibitor, in people with knee osteoarthritis: exclusions at screening

    Ali Guermazi1, Philip Conaghan2, C Michael Perkins3, Claire Herholdt4, Iwona Bombelka5 and Simon Westbrook6, 1Boston University, West Roxbury, MA, 2University of Leeds, Leeds, United Kingdom, 3Levicept, Sandwich, United Kingdom, 4Levicept Ltd, Ashtead, United Kingdom, 5Levicept, Sandwich, Kent, United Kingdom, 6Levicept Ltd, Sandwich, United Kingdom

    Background/Purpose: LEVI-04 is a first-in-class fusion protein (p75NTR-Fc) that supplements the endogenous p75NTR binding protein, providing analgesia via inhibition of NT-3 activity. Like p75NTR, LEVI-04…
  • Abstract Number: 1951 • ACR Convergence 2025

    Quantitative HRCT Analysis in Sjögren’s Disease-associated ILD: CALIPER-Derived Imaging Biomarkers for Prognostic Assessment

    Gaetano La Rocca1, Francesco Ferro2, Vincenzo Uggenti3, Beatrice Dei4, Giovanni Fulvio4, Michele Moretti4, Marta Mosca5, Chiara Romei3 and Chiara Baldini5, 1University of Pisa, Rheumatology Unit, Pisa, Pisa, Italy, 2Clinical and Experimental Medicine Department, Azienda Ospedaliero-Universitaria Pisana, Pisa, Pisa, Italy, 3University of Pisa, 2nd Radiology Unit, Pisa, Italy, 4Rheumatology Unit, University of Pisa, Pisa, Toscana, Italy, 5University of Pisa, Pisa, Pisa, Italy

    Background/Purpose: Interstitial Lung Disease (ILD) is a frequent manifestation of Sjögren’s Disease (SjD), associated with significant morbidity and mortality. However, data on the prevalence of…
  • Abstract Number: 1680 • ACR Convergence 2025

    Major salivary gland ultrasonographic features of lymphoma and high lymphoproliferative risk lesions in Sjögren’s Disease: a systematic review

    Alen Zabotti1, Valeria Manfrè1, Maria Teresa Rizzo1, Alessia Nano1, Garifallia Sakellariou2 and Luca Quartuccio1, 1Division of Rheumatology, Department of Medicine (DMED), Academic Hospital "Santa Maria della Misericordia", ASUFC, University of Udine, Udine, Italy, Udine, Italy, 2Department of Internal Medicine and Therapeutics, Università Di Pavia, Pavia, Italy; Istituti Clinici Scientifici Maugeri IRCCS Pavia, Pavia, Italy

    Background/Purpose: Sjögren's disease (SjD) is burdened by significant lymphoproliferative risk. Up to date there is no established consensus on the salivary gland ultrasonographic (SGUS) features…
  • Abstract Number: 1213 • ACR Convergence 2025

    Transitional Changes on High Resolution Computed Tomography (HRCT) in idiopathic inflammatory Myopathy- Associated Interstitial Lung Disease (IIM-ILD)

    Sangmee Bae1, Grace Kim2, Jihey Lee2, Daniela Markovic2, Donald Tashkin2, Jonathan Goldin2, Rohit Aggarwal3 and Christina Charles-Schoeman4, 1UCLA Rheumatology, Los Angeles, CA, 2UCLA, Los Angeles, 3University of Pittsburgh, Rheumatology and Clinical Immunology, Pittsburgh, United States of America, Pittsburgh, PA, 4UCLA Medical Center, Santa Monica, CA

    Background/Purpose: HRCT is used as a surrogate for important histopathological findings when evaluating patients with interstitial lung disease (ILD). Quantitative imaging analysis (QIA) using CT…
  • Abstract Number: 0759 • ACR Convergence 2025

    Distinct differences between giant cell arteritis diagnosed by fluorodeoxyglucose (FDG) positron emission tomography (PET) versus temporal artery biopsy-a comparative cohort study

    Sehreen Mumtaz1, Lerone Clark2, Archit Srivastava2, Hannah Langenfeld3, Andrew C. Hanson3, Cynthia Crowson4, Andy Abril2, Nouran Eshak5, Megan Sullivan6, Matthew Koster3 and Kenneth Warrington3, 1Mayo Clinic Florida, Jacksonville, FL, 2Mayo Clinic, Florida, Jacksonville, FL, 3Mayo Clinic, Rochester, MN, 4Mayo Clinic, Stewartvillle, MN, 5Mayo Clinic, Arizona, Scottsdale, AZ, 6Mayo Clinic Arizona, Scottsdale, AZ

    Background/Purpose: Giant cell arteritis (GCA) is clinically heterogenous, and the presenting manifestations may influence diagnostic testing. The aim of this study was to evaluate the…
  • Abstract Number: 0227 • ACR Convergence 2025

    Malignancy Screening of Dermatomyositis Patients in the Penn State Registry of Inflammatory Myopathies (PRIMO)

    Katrina Gonzales1, William DeKryger2, Deepika Pugalenthi Saravanan2, Esha Tulsian2, Peri Newman3, Jacob Colello2, Galen Foulke4 and Nancy Olsen5, 1Penn State College of Medicine, Hummelstown, PA, 2Penn State College of Medicine, Hershey, PA, 3Penn State Health/ Penn State College of Medicine, Hershey, PA, 4Penn State Health, Hershey, PA, 5Penn State University/Milton S Hershey, Hershey, PA

    Background/Purpose: Dermatomyositis (DM) is an immune-mediated myopathy characterized by muscle weakness and skin rash that carries an elevated risk of associated malignancy within 5 years…
  • Abstract Number: 2611 • ACR Convergence 2025

    Exploring the Role of a Lung Ultrasound Score in the Assessment of Severity of Connective Tissue Disease-Related Interstitial Lung Disease

    jin ding1, ying zhang1, Linxuan Pang1, ning guo2 and zhaohui zheng1, 1Department of Clinical Immunology, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China (People's Republic), 2Department of Radiology, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China (People's Republic)

    Background/Purpose: The role of lung ultrasound (LUS) in assessing disease severity of interstitial lung disease (ILD) remains unclear. We employed a semiquantitative scoring system to…
  • Abstract Number: 1971 • ACR Convergence 2025

    Intracranial Arterial Stenosis in Antiphospholipid Syndrome: A Neglected Vascular Involvement?

    Yuying Fan1, Jinyi Qian1, Xiaohan Wei2, Haoyu Pan1, Shuyi Yu1, Zhixia Yang1, Shiyan Gu1, Jianzhou Wu1, Cenyi Wang1, Tiancheng Zhou1 and Hui Shi3, 1Department of Rheumatology and Immunology, Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China, Shanghai, Shanghai, China (People's Republic), 2Shanghai JiaoTong University, Shanghai, China (People's Republic), 3Shanghai Jiaotong University Affiliated Ruijin Hospital, Shanghai, China (People's Republic)

    Background/Purpose: Antiphospholipid syndrome (APS) is a systemic autoimmune disorder characterized by thrombotic events and obstetric complications. While macrovascular and microvascular manifestations have been increasingly acknowledged—particularly…
  • Abstract Number: 1950 • ACR Convergence 2025

    Pericoronary fat enhancement in rheumatoid arthritis differs from controls and associates with coronary atherosclerosis independently of epicardial fat volume

    Frederik Enevoldsen1, Sarah Ormseth2, Dzenan Masic1, Matthew Budoff3, Ellen-Margrethe Hauge1 and George Karpouzas3, 1Aarhus University, Aarhus, Denmark, 2The Lundquist Institute for Biomedical Innovation, Torrance, CA, 3Harbor-UCLA Medical Center, Torrance, CA

    Background/Purpose: Pericoronary adipose tissue attenuation (PCATa) reflects the composition of the fat directly surrounding the coronary arteries and is associated with coronary wall inflammation. In…
  • Abstract Number: 1664 • ACR Convergence 2025

    Cardiac Sarcoidosis Response to Steroid-Sparing Immunosuppression

    Alexia Zagouras1, Sammy Pickell1, Yuhan Liu1, Ronald Witteles1 and Matthew Charles Baker2, 1Stanford University, Stanford, CA, 2Stanford University, Menlo Park, CA

    Background/Purpose: There are no FDA-approved therapies for cardiac sarcoidosis (CS), a disease associated with high morbidity and mortality. Treatment typically consists of glucocorticoids and off-label…
  • « Previous Page
  • 1
  • …
  • 3
  • 4
  • 5
  • 6
  • 7
  • …
  • 43
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology